Drug intelligence / Profile preview

prednicarbate + octenidine

Development stage: Phase 2
Lead developer: Almirall
Modality: Small Molecules
Administration: Topical

Overview

LAS41003 is a topical combination drug developed by Almirall for the treatment of inflammatory skin conditions such as tinea pedis (athlete's foot), candidiasis, and atopic dermatitis. The formulation combines prednicarbate—a glucocorticoid receptor agonist corticosteroid—with octenidine, an antiseptic agent. Its mechanism of action involves anti-inflammatory effects via glucocorticoid receptor activation (prednicarbate) and antimicrobial activity (octenidine). The drug was investigated in multiple Phase 2 clinical trials for dermatological indications but has not been approved or marketed[2][4][7].

Other names: prednicarbate/octenidineoctenidine/prednicarbateLAS189961/LAS189962

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on prednicarbate + octenidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prednicarbate + octenidine.

Explore the full profile